Improvement of spatial fibrin formation by the anti‐TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation

@article{Parunov2011ImprovementOS,
  title={Improvement of spatial fibrin formation by the anti‐TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation},
  author={Leonid A Parunov and Olga A. Fadeeva and A. N. Balandina and Natalia P. Soshitova and Konstantin G. Kopylov and Maria A. Kumskova and James C. Gilbert and Robert Schaub and Kathleen E. McGinness and Fazoil I. Ataullakhanov and Mikhail A. Panteleev},
  journal={Journal of Thrombosis and Haemostasis},
  year={2011},
  volume={9}
}
Summary.  Background: Tissue factor pathway inhibitor (TFPI) is a major regulator of clotting initiation and a promising target for pro‐ and anticoagulation therapy. The aptamer BAX499 (formerly ARC19499) is a high‐affinity specific TFPI antagonist designed to improve hemostasis. However, it is not clear how stimulation of coagulation onset by inactivating TFPI will affect spatial and temporal clot propagation. Objective: To examine the BAX499 effect on clotting in a spatial, reaction‐diffusion… 
Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
TLDR
Investigation of the cooperative effect of TFPI inhibition and supplementation of FVIII in hemophilia A in a spatial, reaction-diffusion experiment in vitro indicates that BAX499 has an effect on clotting in hemophile A plasma at low FVII concentrations, however has little effect at high FV III concentrations.
Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.
TLDR
It is concluded that, under flow, TFPI-α is capable to antagonize fibrin formation in a manner dependent on and restricted by local TF/factor VIIa and factor Xa activities.
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
TLDR
The data suggest that inhibition of TFPI by BAX499 may have potential for hemophilia treatment but requires further study in blood-based Hemophilia systems.
Sensitivity and Robustness of Spatially Dependent Thrombin Generation and Fibrin Clot Propagation.
Blood coagulation is a delicately regulated space- and time-dependent process that leads to the formation of fibrin clots preventing blood loss upon vascular injury. The sensitivity of the
Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
TLDR
Inhibition of TFPI might be a promising novel treatment approach, especially in haemophilia patients with FVIII inhibitors, particularly when FV III is missing.
The method of in vivo evaluation of hemostasis: Spatial thrombodynamics
TLDR
Thrombodynamics is a promising method for measuring coagulation by imitation of in vivo conditions, and is being used in basic research and in patients with sepsis.
Influence of temperature on spatial fibrin clot formation process in thrombodynamics assay
TLDR
The thrombodynamics assay provided additional arguments supporting the viewpoint, that the temperature lowering itself insignificantly influences the state of the plasma hemostasis system.
Thrombin inhibitors based on single-stranded DNA aptamers
TLDR
It was shown that 31TBA was 2–3 times more effective than 15TBA and both aptamers were stable in human plasma and whole blood in vitro, indicating that the 3’-exonuclease could not be the reason for fast decrease of aptamer’ functional activity in vivo.
Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor.
TLDR
This review focuses on posttranscription and translational modification of TFPI and its function in thrombosis and how pharmacological inhibitors and endogenous proteases interfere with TFPi and alter haemostasis.
Hemostatic properties of a TFPI antibody.
TLDR
The monoclonal antibody, mAb 2021, is one such antagonist directed towards the Kunitz-type protease inhibitor (KPI-2 domain of TFPI which is now being tested in preclinical and clinical trials.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
The Impact of Tissue Factor Pathway Inhibitor on Coagulation Kinetics Determined by Thrombelastography
TLDR
In settings involving heparin administration (e.g., cardiopulmonary bypass), TFPI-mediated inhibition of coagulation should be considered during TEG-based hemostatic monitoring.
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
TLDR
ARC19499 restored thromboelastography clotting times to baseline levels and corrected bleeding times, demonstrating that ARC19499 inhibition of TFPI may be an effective alternative to current treatments of bleeding associated with hemophilia.
Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.
TLDR
Both bleeding and coagulation parameters indicated that blocking of TFPI may be potentially haemostatic in haemophilia.
Effect of factor VIII on tissue factor-initiated spatial clot growth.
TLDR
It is indicated that the functioning of the intrinsic tenase complex is critical for normal spatial clot growth in healthy donors or patients with severe Haemophilia A.
Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution
TLDR
The results indicate that 300–1600 nmol/l (megadoses) of rVIIa may deliver coagulation outside of the TF-rich areas of blood vessel damage via the platelet-derived microparticles.
Regulation of thrombin generation by TFPI in plasma without and with heparin.
TLDR
The results revealed that TFPI and AT acted in synergy as inhibitors of coagulation in terms of the effect on both initiation (lag time) and propagation of TG in a physiological plasma milieu with and without heparin.
Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa
TLDR
This mechanism explains the difference between red and white thrombi observed in vivo at different shear rates and can be speculated that this is a special switch protecting vascular system from uncontrolled formation and spreading of active coagulation factors in vessels with rapidly flowing blood.
Initiation and propagation of coagulation from tissue factor‐bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate *
TLDR
The role of TF‐bearing initiator cells is concluded to be limited to the initial stage of clot formation, and the functioning of intrinsic Xase in plasma provides the primary mechanism of sustained and far‐ranging propagation of coagulation leading to the physical expansion of a fibrin clot.
Hemophilia A and B are associated with abnormal spatial dynamics of clot growth.
TLDR
The results suggest that clot growth is a process consisting of two distinct phases, initiation and elongation, irrespective of the activation pathway.
Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II*
The effects of the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI), antithrombin-III (AT-III) and heparin cofactor-II (HC-II) on thrombin generation were evaluated in a reaction
...
1
2
3
...